Finoriq research workspace
REPLIGEN CORP (RGEN) SEC Filings & Filing Highlights
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing. Review RGEN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
- Company
- REPLIGEN CORP (RGEN)
- Ticker
- RGEN
- Market Cap
- $8.2B
- Latest Price
- $146.14
- Industry
- Biotech & Pharma
REPLIGEN CORP (RGEN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for REPLIGEN CORP (RGEN).
| Event | Form | Date |
|---|---|---|
| i. to elect the nine director nominees identified in the Proxy Statement to the Company’s Board...On May 14, 2026, Repligen Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As of March... | 8-K5.07 | 2026-05-15 |
| Repligen CorporationRepligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance | 8-K2.02 | 2026-05-05 |
| Repligen CorporationRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | 8-K2.02 | 2026-02-24 |
| Repligen CorporationREPLIGEN Executive chair tony hunt to retire; Dr. martin D. MadAus elected chair | 8-K7.01 | 2026-01-06 |
| On January 6, 2026, Repligen Corporation (the “Company”) announced that the Board of Directors...On January 6, 2026, Repligen Corporation (the “Company”) announced that the Board of Directors (the “Board”) has elected Dr. Martin D. Mada... | 8-K5.02 | 2026-01-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.